No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XCUR Exicure
- 0.5181
- +0.0091+1.79%
Trading Apr 26 11:43 ET
4.48MMarket Cap0.29P/E (TTM)
0.5290High0.5000Low19.39KVolume0.5180Open0.5090Pre Close9.94KTurnover0.25%Turnover RatioLossP/E (Static)8.65MShares1.500052wk High0.46P/B4.04MFloat Cap0.364752wk Low--Dividend TTM7.81MShs Float115.2000Historical High--Div YieldTTM5.70%Amplitude0.3647Historical Low0.5120Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Exicure Gets Nasdaq Delinquency Notice On Late Filing Of Its Form 10-K
Express News | Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of Its Form 10-K
5 Value Stocks In The Healthcare Sector
What is a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersChina SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap stands at $2.2 million. Titan Pharma (NASDAQ:TTNP) stock moved
Exicure XCUR Patent Agreement With Bluejay; Helius HSDT FDA Feedback
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersExicure (NASDAQ:XCUR) shares rose 55.5% to $0.87 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.5 million. InVivo Therapeutics Hldg (NASDAQ:NVIV) sha
Comments
$Exicure(XCUR.US$ Will go higher
Update
$Exicure(XCUR.US$ EXICURE XCUR PATENT AGREEMENT WITH BLUEJAY; HELIUS HSDT FDA FEEDBACK
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
1
3
it somewhere in my brain.LOLUpdate
$Exicure(XCUR.US$ Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
5 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
5 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg